# Ensysce Biosciences, Inc. Common Stock (ENSC)

> Ensysce Biosciences, Inc. Common Stock (ENSC) trades at $0.3600 (-0.17%) as of 7:50:07 PM EST on Nov 20, 2026, -29.55% over the past month. Market cap is $7M, with 1.0 days to cover in short interest.

Canonical: https://massive.com/quote/ensc
Data as of: 2026-11-21T00:50:07.985Z (15-minute delayed)
Source: Massive (https://massive.com/docs/llms.txt)

## Price

**$0.3600** -0.00 (-0.17%)
At close · 15-minute delayed
Nasdaq · usd

After hours: **$0.4099** +0.05 (+13.86%)
As of 7:50:07 PM EST on Nov 20, 2026 · After hours

## Stock performance

How Ensysce Biosciences, Inc. Common Stock (ENSC) stock has performed from one day to one year, with its 52-week range.

| Period | Return |
| --- | --- |
| 1D | -0.17% |
| 1W | -13.96% |
| 1M | -29.55% |
| YTD | -60.87% |
| 1Y | -78.44% |
| 52-wk range | $0.23 – $1.85 |

From daily closes through Nov 20, 2026.

## Key statistics

Today's trading snapshot for ENSC: day range, open, previous close, volume and market cap.

| Measure | Value |
| --- | --- |
| Day range | $0.36 – $0.37 |
| Open | $0.36 |
| Prev close | $0.36 |
| Volume | 83.39K |
| Market cap | $7M |
| Shares out | 19.46M |

## Valuation and profitability ratios

Valuation and profitability ratios for Ensysce Biosciences, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

| Measure | Value |
| --- | --- |
| P/E | — |
| P/S | 1.13 |
| P/B | 0.26 |
| P/FCF | — |
| ROE | -332.4% |
| ROA | -294.7% |
| Debt/Equity | 0.01 |
| Div yield | 0.00% |

As of Nov 20, 2026

## Insider trading

[Ensysce Biosciences, Inc. Common Stock (ENSC) insider trading](https://massive.com/quote/ensc/insider-trading.md): open-market Form 4 buys and sells by Ensysce Biosciences, Inc. Common Stock insiders over the last 12 months.

## 8-K filings

Material corporate events Ensysce Biosciences, Inc. Common Stock has disclosed to the SEC on Form 8-K.

- Nov 4, 2026 · Executive officer appointment
  ““Dr. Lynn Kirkpatrick ... agreed that she would assume the title of Chief Operating Officer of the Company immediately following the Annual Meeting.””
- Sep 29, 2026 · Preferred stock modification
  “On September 25, 2026, the Company amended the Series C Certificate of Designation to remove Section 6.5.3 and other references to Section 6.5.3 in the Series C Certificate of Designation (the “Amendment”). Section 6.5.3 provides that the Series C Preferred Stock is redeemable for cash at the option of the holder thereof under specified circumstances. The Amendment was effective upon filing.”
- Aug 25, 2026 · [Listing deficiency notice](https://massive.com/quote/sec-filings/8-k/delisting-notices.md)
  “On August 25, 2026, Nasdaq granted the Company an additional 180 calendar days, or until February 22, 2027, to regain compliance with the Minimum Price Listing Requirement.”
- Aug 24, 2026 · Private placement
  “Pursuant to the Securities Purchase Agreement, the Company agreed to issue and sell an aggregate of 120,260 shares of its Series C Preferred Stock for an aggregate purchase price of approximately $43 million (the "Financing") to be purchased in two tranches. At the closing of the first tranche of the Financing (the "Initial Closing") that occurred on August 7, 2026, the Company raised more than $21 million in gross proceeds.”
- Aug 6, 2026 · Executive officer appointment
  “Pursuant to the Merger Agreement, on August 4, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee of the Board, appointed James Morrison as President and as a director of the Company effective immediately upon the Closing and appointed Mr. Morrison as Chief Executive Officer effective upon approval of the Meeting Proposals.”

## Dividend history and stock splits

Ensysce Biosciences, Inc. Common Stock's recent dividend payments and stock splits.

### Dividends

No recent dividends.

### Splits

- 1-for-15 · Dec 6, 2024
- 1-for-12 · Mar 31, 2023
- 1-for-20 · Oct 28, 2022

## ENSC short interest

How heavily ENSC is shorted: shares short, days to cover and average daily volume.

| Measure | Value |
| --- | --- |
| Days to cover | 1.0 |
| Short interest | 88.61K |
| Avg volume | 264.79K |

As of Oct 30, 2026 · reported to FINRA twice monthly.

## ENSC news

The latest news and headlines about Ensysce Biosciences, Inc. Common Stock (ENSC).

- [Tiny Pain-Focused Biotech Ensysce Biosciences Surges Amid Strategic Review](https://www.benzinga.com/news/health-care/26/02/50936032/tiny-pain-focused-biotech-ensysce-biosciences-surges-amid-strategic-review?utm_source=benzinga_taxonomy&utm_medium=rss_feed_free&utm_content=taxonomy_rss&utm_campaign=channel) · Benzinga · Feb 27, 2026 · positive sentiment
- [Follow-Through Leaders: Production Ramps, AI Alliances, Balance Sheet Strength](https://www.globenewswire.com/news-release/2026/02/27/3246589/0/en/Follow-Through-Leaders-Production-Ramps-AI-Alliances-Balance-Sheet-Strength.html) · GlobeNewswire Inc. · Feb 27, 2026 · positive sentiment
- [Chronic and Acute Pain Clinical Trial Pipeline Analysis: 150+ Key Companies Shaping the Future of Chronic and Acute Pain Therapeutics \| DelveInsight](https://www.globenewswire.com/news-release/2026/01/28/3227952/0/en/Chronic-and-Acute-Pain-Clinical-Trial-Pipeline-Analysis-150-Key-Companies-Shaping-the-Future-of-Chronic-and-Acute-Pain-Therapeutics-DelveInsight.html) · GlobeNewswire Inc. · Jan 28, 2026 · positive sentiment
- [Diamond Equity Research Releases Update Note on Ensysce Biosciences, Inc. (NASDAQ: ENSC)](https://www.globenewswire.com/news-release/2025/08/15/3134183/0/en/Diamond-Equity-Research-Releases-Update-Note-on-Ensysce-Biosciences-Inc-NASDAQ-ENSC.html) · GlobeNewswire Inc. · Aug 15, 2025 · positive sentiment
- [Ensysce Biosciences Narrows Loss in Q2](https://www.fool.com/data-news/2025/08/13/ensysce-biosciences-narrows-loss-in-q2/?source=iedfolrf0000001) · The Motley Fool · Aug 13, 2025 · neutral sentiment

## About Ensysce Biosciences, Inc. Common Stock

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses. Its products are anticipated to provide safer options to treat severe pain and assist in preventing deaths caused by opioid abuse, reducing human and economic costs. The company's current development pipeline includes two new drug platforms: an abuse-resistant opioid prodrug technology, theTrypsin Activated Abuse Protection, or the TAAP platform, and an over-dose protection opioid prodrug technology, the Multi-Pill Abuse Resistant, or the MPAR platform. The Company currently operates in one business segment, which is pharmaceuticals.

| Measure | Value |
| --- | --- |
| Exchange | Nasdaq |
| Market | stocks |
| Type | CS |
| Currency | USD |
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 10 |
| Listed | Jul 1, 2021 |

[Company website](https://www.ensysce.com)

## FAQ

### What is the Ensysce Biosciences, Inc. Common Stock (ENSC) stock price today?

Ensysce Biosciences, Inc. Common Stock (ENSC) is trading at $0.3600 (-0.17% on the day) as of 7:50:07 PM EST on Nov 20, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

### What is Ensysce Biosciences, Inc. Common Stock?

Ensysce Biosciences Inc is a clinical-stage biotech company using its proprietary technology platforms to develop safer prescription drugs. The company is developing a new class of powerful, opioids that prevent both drug abuse and overdoses.

### What is the short interest in ENSC?

As of Oct 30, 2026, ENSC has 88.61K shares short and 1.0 days to cover.

### What exchange is ENSC listed on?

Ensysce Biosciences, Inc. Common Stock (ENSC) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.

## Live data

Prices here are 15-minute delayed. For real-time ENSC quotes and the full history behind this page, use the Massive API or MCP server:

- `GET https://api.massive.com/v3/snapshot?ticker.any_of=ENSC`

Requests need a Massive API key. API reference for agents: https://massive.com/docs/llms.txt. Connect an AI agent through the Massive MCP server: https://massive.com/docs/ai-tools.

## Related

- [Ensysce Biosciences, Inc. Common Stock (ENSC) insider trading](https://massive.com/quote/ensc/insider-trading.md)
- [SEC 8-K events](https://massive.com/quote/sec-filings/8-k.md)
- [Markets overview](https://massive.com/quote/index.md)

Nothing here is investment advice. Data and content are provided for informational purposes under the Massive Terms of Service: https://massive.com/terms
